AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claim 1. (currently amended): ~~Novel~~ ω-naphthyloxy amino alkane derivatives having structural formula I,



I

Wherein R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon atoms~~, such as~~ selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl~~,~~ and hexyl; a branched chain lower alkyl ~~such as~~ selected from the group consisting of isopropyl, isobutyl, t-butyl and alkyl chains thereof~~.~~; a cyclic alkane ~~such as~~ selected from the group consisting of cyclopropyl, cyclobutyl, cyclohexyl, cycloheptyl and cyclic alkanes thereof~~.~~; a lower alkoxy in which the alkyl group is as mentioned above, n is 1 to 6; R_3 and R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined~~–~~ above; an aryl residue selected from the group ~~comprising~~ consisting of phenyl~~,~~ ~~substituted phenyl~~ and naphthyl; an arylalkyl residue selected from the group ~~comprising~~ consisting of benzyl~~,~~ and substituted benzyl, form a part of a heterocylic ring selected from the group ~~comprising~~ consisting of pyrrolidine and ~~,~~piperidine, form ~~–~~a heterocylic ring with

additional heteroatoms O,N,S selected from the group ~~comprising~~ consisting of piperazine, morpholine, oxazole, oxathinazole~~,~~ and oxathiazine ~~etc.~~; an alkoxy carbonyl alkane represented by the formula ~~selected from~~ R_6COOR_7, wherein R_6 is $(CH_2)n$ (n=1-3) and R_7 is a lower alkyl as defined above~~.~~, provided that either R_1 and R_2 or R_3 and R_4 are not both H.

Claim 2. (currently amended): ~~Novel~~ ω-naphthyloxy amino alkane derivatives as claimed in claim 1 ~~includes~~selected from the group consisting of:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]amine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl] amine~~.~~ [I: R_1= R_2=H, R_3= propyl R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester~~.~~ [I: R_1=R_2=H, R_3=CH_2COOEt,R_4=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I:R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)butylamine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=3]

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H,R_4= benzyl, n=4]

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I : R_1 = R_2 = R_3 = H, R_4 = cylohexyl-, n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I-: $R_1 = R_2 = R_3 = H$, $R_4 =$ cylohexyl,n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:$R_1=R_2=R_3=H$, R_4 = cylohexyl,n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]amine [I : $R_1 = R_2 = R_3 = H$,R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine[I:$R_1=R_2=$ $R_3=$ H, R_4=2-ethyl- n-hexyl, n=3].

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl] amine[I:$R_1=R_2=R_3=H$,R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:$R_1=R_2=R_3=$ H,$R_4=$ n-dodecyl,n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:$R_1= R_2 = R_3 =$ H, R_4=n-dodecyl,n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I:$R_1=R_2=$ $R_3=$ H,$R_4=$ n-dodecyl,n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:$R_1=R_2 = R_3 =$ H,$R_4=$ isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]amine[I:$R_1=R_2=R_3=H$ R_4 = isoamyl, n =3]

(xxviii)N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I : $R_1 = R_2 = R_3 = H$, R_4 = isoamyl,n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:$R_1=R_2= R_3=H$, R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: $R_1=R_2=R_3=$ H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: $R_1=R_2=R_3=H$, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: $R_1=R_2=R_3=H$, R_4=n-octyl, n=2]

(xxxiii)N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]amine [I: $R_1=R_2=R_3=H$, R_4=n-octyl, n=3]

(xxxiv)N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: $R_1=R_2=R_3=H$, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: $R_1=R_2=R_3=H$, R_4=n-butyl, n=4]

(xxxvi)N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: $R_1=R_2=R_3=H$, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I, $R_1=R_2=R_3=H$, R_4=2-phenyl- ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=4]

(xxxix) N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propyl]amine, [I, R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4 Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl]—amine, [I, R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl] amine[I,R_1=R_2=H, R_3= n-butyl, R_4=4-Methoxyphenyl, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester[I, R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-Methoxyphenyl, n=3]

(xlviii) 2,7-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

and

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl].

Claim 3. (original): Derivatives as claimed in claim 1, wherein said derivatives are useful for treatment and prevention of hyperglycemia and cardiovascular disorders (CVS) in mammals, including humans.

Claim 4. (original): Derivatives as claimed in claim 1, wherein the said derivatives can be administered as pharmaceutical composition optionally along with acceptable salt/s, carrier/s or dilutent/s.

Claim 5. (currently amended): Derivatives as claimed in claim 4, wherein the salts/carriers/diluents are selected from the ~~a~~ group ~~comprising~~ consisting of lactose, sodium chloride, potassium chloride, magnesium sulphate, magnesium chloride, potassium sulfate, sodium sulfate, lithium sulphate, sodium phosphate, potassium phosphate, magnesium succinate, sodium carbonate, sodium sulfate, potassium acid phosphate ~~or~~ and calcium bicarbonate.

Claim 6. (original): Derivatives as claimed in claim 1 wherein the dosage of the said derivatives is in the range of about 250-350 µmol/Kg.,

Claim 7. (original): Derivatives as claimed in claim 6 wherein, the dosage of the said derivatives is preferably about 300 µmol/Kg.

Claim 8. (original): Derivatives as claimed in claim 1, wherein said derivatives may be administered in form syrup, capsule, tablet, intravenous, liquid or suspension.

Claim 9. (original): Derivatives as claimed in claim 1, wherein method of administration for said derivatives may be oral, nasal, rectoral, or parenteral.

Claim 10. (original): Derivatives as claimed in claim 1, wherein said derivatives lower the concentration of cholesterol by about 30%.

Claim 11. (currently amended): Derivatives as claimed in claim 10, wherein said derivatives lower the concentration of cholesterol ~~preferably~~ by about 26%.

Claim 12. (original): Derivatives as claimed in claims 1 wherein said derivatives lower the concentration of phospholipid by about 35 %.

Claim 13. (currently amended): Derivatives as claimed in claim 12, wherein said derivatives lower the concentration of phospholipid ~~preferably~~ by about 30%.

Claim 14. (original): Derivatives as claimed in claim 1 wherein said derivatives lower the concentration of Triglyceride by about 50 %.

Claim 15. (currently amended): Derivatives as claimed in claim 14 wherein said derivatives lower the concentration of Triglyceride ~~preferably~~ by about 48%.

Claim 16. (currently amended): Derivatives as claimed in claim 1 wherein said derivatives enhance the concentration of high-density lipoprotein (HDL) by about 20 %.

Claim 17. (currently amended): Derivatives as claimed in claim 16 wherein said derivatives enhance the concentration of high-density lipoprotein ~~preferably~~ by about 15%.

Claim 18. (original): Derivatives as claimed in claim 1 wherein said derivatives lowers the glucose (GLU) concentration by about 35 %.

Claim 19. (currently amended): Derivatives as claimed in claim 18 wherein said derivatives lower the glucose concentration ~~preferably~~ by about 30%.

Claim 20. (original): Derivatives as claimed in claim 1 wherein said derivatives lowers the glycerol (GLY) concentration by about 20 %.

Claim 21. (currently amended): Derivatives as claimed in claim 1 wherein said derivatives lowers the glycerol (GLY) concentration ~~preferably~~ by about 14 %.

Claim 22. (original): Derivatives as claimed in claim 1 wherein said derivatives lower the glucose concentration in about 30 min to 10 hours during post drug administration.

Claim 23. (original): Derivatives as claimed in claim 22 wherein, the derivatives lower the glucose concentration in about 1 hr to 7 hrs during post drug administration.

Claim 24. (currently amended): A method for preparing ω-naphthyloxy amino alkane derivatives having structural formula I,



I

Wherein R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon atoms~~, such as~~ selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl~~,~~ and hexyl; a branched chain lower alkyl ~~such as~~ selected from the group consisting of isopropyl, isobutyl~~,~~ and t-butyl ~~etc.~~; a cyclic alkane ~~such as~~ selected from the group consisting of cyclopropyl, cyclobutyl, cyclohexyl~~,~~ and cycloheptyl ~~etc.~~; a lower alkoxy in which the alkyl group is as mentioned above, n is 1 to 6; R_3 and R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined above; an aryl residue ~~such as~~ selected from the group consisting of phenyl, substituted phenyl~~,~~ and naphthyl; an arylalkyl residue ~~such as~~ selected from the group consisting of benzyl~~,~~ and substituted benzyl, form a part of a heterocylic ring ~~such as~~ selected from the group consisting of pyrrolidine~~,~~ and piperidine, form a heterocylic ring with additional heteroatoms O,N,S ~~such as~~ selected from the group consisting of piperazine, morpholine, oxazole, oxathinazole and~~,~~ oxathiazine ~~etc.~~; an alkoxy

carbonyl alkane ~~such as~~represented by the formula R_6COOR_7, wherein R_6 is $(CH_2)n$ (n=1-3) and R_7 is a lower alkyl as defined above, said process comprising steps of:

~~(b)~~(a) reacting substituted β-naphthol of Formula II with dihaloalkane of formula III in an organic solvent in the presence of a base to obtain an intermediate compound of formula IV, ~~and~~



Wherein R_1 and R_2 are defined as above and wherein X_1 and X_2 may be same or different halogens, and

~~(c)~~(b) reacting compound of formula IV with an amine of formula V in presence of an acid binding agent optionally in an organic solvent to obtain compound of formula I, wherein X_2 is a halogen and R_3 and R_4 are defined as above.

Claim 25. (currently amended): A method as claimed in claim 24, wherein said derivatives ~~includes~~ are selected from the group consisting of:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]amine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl] amine [I: R_1= R_2=H, R_3= propyl R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester [I: R_1=R_2=H, R_3=CH_2COOEt,R_4=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I:R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)butylamine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=3]

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H,R_4= benzyl, n=4]

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I–: R_1 = R_2 = R_3 = H, R_4 = cylohexyl-, n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I : R_1 = R_2 = R_3 =H, R_4 = cylohexyl,n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H, R_4 = cylohexyl,n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]amine [I : R_1 = R_2 = R_3 = H,R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=2-ethyl- n-hexyl, n=3].

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl] amine[I:R_1=R_2=R_3=H ,R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3= H,R_4= n-dodecyl,n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1= R_2 = R_3 = H, R_4=n-dodecyl,n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2= R_3= H,R_4= n-dodecyl,n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2 = R_3 = H,R_4= isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]amine[I:R_1=R_2=R_3=H R_4 = isoamyl, n =3]

(xxviii)N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I : R_1 = R_2 = R_3 = H , R_4 = isoamyl,n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:R_1=R_2= R_3=H , R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1=R_2=R_3= H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=2]

(xxxiii)N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=3]

(xxxiv)N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-butyl, n=4]

(xxxvi)N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl- ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=4]

(xxxix)N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propyl]amine, [I, R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4 Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl] amine. [I, R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl] amine[I,R_1=R_2=H, R_3= n-butyl, R_4=4-Methoxyphenyl, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester[I, R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-Methoxyphenyl, n=3]

(xlviii) 2,7-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

and

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl].

Claim 26. (currently amended): A method as claimed in claim 24, wherein the organic ~~solvents~~ solvent in step (a) ~~are~~is selected from the group ~~comprising~~ consisting of dry acetone, ethanol, methanol, dimethyl sulphoxide (DMSO), dimethylformamide (DMF), Hexamethylphosphoric triamide (HMPA) ~~,~~and acetonitrile ~~or other organic compounds~~.

Claim 27. (currently amended): A method as claimed in claim 24, wherein the base in step (a) is selected from a group ~~comprising~~ consisting of cesium carbonate, potassium carbonate, sodium carbonate~~,~~ and lithium carbonate ~~or other bases~~.

Claim 28. (currently amended): A method as claimed in claim 24, wherein the organic ~~solvents~~ solvent in step (b) ~~are~~is selected from the group ~~comprising~~ consisting of dimethyl sulphoxide (DMSO), dimethylformamide (DMF), Hexamethylphosphoric triamide (HMPA) ~~or~~and acetonitrile.

Claim 29. (original): A method as claimed in claim 24, wherein the temperature in step (a) is in range of about 50°C to 100°C,

Claim 30. (currently amended): A method as claimed in claim 29, wherein the temperature is ~~preferably~~ in the range of about 60°C to 80°C.

Claim 31. (original): A method as claimed in claim 24, wherein the temperature in step (b) in the range of about 120°C to 180°C.

Claim 32. (original): A method as claimed in claim 31, wherein the temperature is preferably in the range of about 130°C to 150°C.

Claim 33. (original): A method as claimed in claim 24, wherein the reaction time in steps (a) and (b) is in range of about 4 hours to 13 hours.

Claim 34. (original): A method as claimed in claim 33, wherein the reaction time in steps (a) and (b) is in range of about 5 hours to 12 hours.

Claim 35. (original): A method as claimed in claim 24, wherein the derivatives of formula (1) have their melting points in the range of about 75°C to 170°C.

Claim 36. (currently amended): A method as claimed in claim 35, wherein the derivatives of formula (1) have their melting points in the range of about 78°C to 160°C.

Claim 37. (currently amended): A method as claimed in claim 24, wherein the purity of the said derivatives of formula (~~I~~I) is in the range of about 80% to 100%.

Claim 38. (original): A method as claimed in claim 24, wherein the dosage of the said derivatives is in the range of about 250-350 μmol/Kg.

Claim 39. (currently amended): A method as claimed in claim 38, wherein the dosage of the said derivatives is ~~preferably~~ about 300 μmol/Kg.

Claim 40. (original): A method as claimed in claim 24, wherein the said derivatives may be administered in form of syrup, capsule, tablet, suspension or intravenous.

Claim 41. (currently amended): A method as claimed in claim 40, wherein the method of administration of said derivatives is~~are~~ oral, nasal, or parenteral.

Claim 42. (original): A method as claimed in claim 24, wherein said derivatives lower the concentration percentage of cholesterol by about 30%.

Claim 43. (currently amended): A method as claimed in claim 42, wherein said derivatives lowers the concentration of cholesterol ~~preferably~~ by about 26%.

Claim 44. (original): A method as claimed in claim 24, wherein said derivatives lower the concentration of phospholipid by about 35 %.

Claim 45. (currently amended): A method as claimed in claim 44, wherein said derivatives lower the concentration of phospholipid ~~preferably~~ by about 30%.

Claim 46. (original): A method as claimed in claim 24, wherein said derivatives lower the concentration of triglyceride by about 50 %.

Claim 47. (currently amended): A method as claimed in claim 46, wherein said derivatives lower the concentration of triglyceride ~~preferably~~ by about 48%.

Claim 48. (original): A method as claimed in claim 24, wherein said derivatives enhance the concentration of high-density lipoprotein (HDL) by about 20 %.

Claim 49. (original): A method as claimed in claim 48, wherein said derivatives enhance the concentration of high-density lipoprotein preferably by about 15%.

Claim 50. (original): A method as claimed in claim 24, wherein said derivatives lower the glucose (GLU) concentration by about 40 %.

Claim 51. (original): A method as claimed in claim 50, wherein said derivatives lower the glucose (GLU) concentration preferably by about 30 %.

Claim 52. (original): A method as claimed in claim 24 wherein said derivatives lower the glycerol (GLY) concentration by about 20 %.

Claim 53. (original): A method as claimed in claim 52 wherein, the dosage of the derivatives lowers the glycerol concentration by about 14 %.

Claim 54. (original): A method as claimed in claim 24, wherein said derivatives lower the glucose concentration in about 30 min to 10 hours during post drug administration.

Claim 55. (original): A method as claimed in claim 54, wherein said derivatives lower the glucose concentration in about 1 hr to 7 hrs during post drug administration.

Claim 56. (currently amended): A pharmaceutical composition for the treatment or prevention of cardiovascular disorders (CVS) and of hyperglycemic condition (diabetes) in mammals, including humans, said composition comprising ~~of administering~~ an effective dosage of ω-naphthyloxy amino alkane derivatives having structural Formula ~~1~~ I,



I

Wherein, R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon atoms~~, such as~~ selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl~~,~~ and hexyl; a branched chain lower alkyl ~~such as~~ selected from the group consisting of isopropyl, isobutyl~~,~~ and t-butyl ~~etc.~~; a cyclic alkane ~~such as~~ selected from the group consisting of cyclopropyl, cyclobutyl, cyclohexyl~~,~~ and cycloheptyl ~~etc.~~; a lower alkoxy in which the alkyl group is as mentioned above,

n is 1 to 6; R_3 and R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined- above; an aryl residue ~~such as~~ selected from the group consisting of phenyl, substituted phenyl~~,~~ and naphthyl; an arylalkyl residue ~~such as~~ selected from the group consisting of benzyl~~,~~ and substituted benzyl, form a part of a heterocylic ring ~~such as~~ selected from the group consisting of pyrrolidine~~,~~ and piperidine, form -a heterocylic ring with additional heteroatoms O,N,S ~~such as~~ selected from the group consisting of piperazine, morpholine, oxazole, oxathinazole ~~,~~and oxathiazine ~~and compounds thereof~~; an alkoxy carbonyl alkane ~~such as~~ represented by the formula R_6COOR_7, wherein R_6 is $(CH_2)n$ (n=1-3) and R_7 is a lower alkyl as defined above, optionally along with acceptable salt/s, carrier/s or dilutent/s, wherein the salts/carriers/diluents are selected from the group consisting of lactose, sodium chloride, potassium chloride, magnesium sulphate, magnesium chloride, potassium sulfate, sodium sulfate, lithium sulphate, sodium phosphate, potassium phosphate, magnesium succinate, sodium carbonate, sodium sulfate, potassium acid phosphate and calcium bicarbonate.~~,~~

Claim 57. (canceled):

Claim 58. (currently amended): A composition as claimed in claim 56 wherein, said derivatives ~~include~~ are selected from the group consisting of:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]amine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl] amine~~.~~[I: R_1= R_2=H, R_3= propyl R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester~~.~~ [I: R_1=R_2=H, R_3=CH_2COOEt,R_4=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I:R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)butylamine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=3]

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H,R_4= benzyl, n=4]

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I : R_1 = R_2 = R_3 = H, R_4 = cylohexyl-, n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I : R_1 = R_2 = R_3 =H, R_4 = cylohexyl,n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H, R_4 = cylohexyl,n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]amine [I : R_1 = R_2 = R_3 = H,R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=2-ethyl- n-hexyl, n=3].

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl] amine[I:R_1=R_2=R_3=H ,R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3= H,R_4= n-dodecyl,n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1= R_2 = R_3 = H, R_4=n-dodecyl,n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2= R_3= H,R_4= n-dodecyl,n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2 = R_3 = H,R_4= isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]amine[I:R_1=R_2=R_3=H R_4 = isoamyl, n =3]

(xxviii)N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I–: R_1 = R_2 = R_3 = H , R_4 = isoamyl,n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:R_1=R_2= R_3=H , R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1=R_2=R_3= H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=2]

(xxxiii)N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=3]

(xxxiv)N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-butyl, n=4]

(xxxvi)N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl- ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=4]

(xxxix)N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propyl]amine, [I, R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4 Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl] amine. [I, R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl] amine[I,R_1=R_2=H, R_3= n-butyl, R_4=4-Methoxyphenyl, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester[I, R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-Methoxyphenyl, n=3]

(xlviii) 2,7-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

and

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl]/

Claim 59. (original): A composition as claimed in claim 56, wherein the dosage of the said derivatives is in the range of about 250-350 μmol/Kg.

Claim 60. (currently amended): A composition as claimed in claim 59, wherein the dosage of the said derivatives is ~~preferably~~ about 300 μmol/Kg.

Claim 61. (original): A composition as claimed in claim 56, wherein the said derivatives may be administered in form of syrup, capsule, tablet, suspension or intravenous.

Claim 62. (currently amended): A composition as claimed in claim 56, wherein the method of administration of said derivatives ~~are~~ is oral, nasal, or parenteral.

Claim 63. (original): A composition as claimed in claim 56, wherein said derivatives lower the concentration percentage of cholesterol by about 30%.

Claim 64. (currently amended): A composition as claimed in claim 63, wherein said derivatives lowers the concentration of cholesterol ~~preferably~~ by about 26%.

Claim 65. (original): A composition as claimed in claim 56, wherein said derivatives lower the concentration of phospholipid by about 35 %.

Claim 66. (currently amended): A composition as claimed in claim 65, wherein said derivatives lower the concentration of phospholipid ~~preferably~~ by about 30%.

Claim 67. (original): A composition as claimed in claim 56, wherein said derivatives lower the concentration of triglyceride by about 50 %.

Claim 68. (currently amended): A composition as claimed in claim 67, wherein said derivatives lower the concentration of triglyceride ~~preferably~~ by about 48%.

Claim 69. (original): A composition as claimed in claim 56, wherein said derivatives enhance the concentration of high-density lipoprotein (HDL) by about 20 %.

Claim 70. (original): A composition as claimed in claim 69, wherein said derivatives enhance the concentration of high-density lipoprotein preferably by about 15%.

Claim 71. (original): A composition as claimed in claim 56, wherein said derivatives lower the glucose (GLU) concentration by about 40 %.

Claim 72. (currently amended): A composition as claimed in claim 71, wherein said derivatives lower the glucose (GLU) concentration ~~preferably~~ by about 30 %.

Claim 73. (currently amended): A composition as claimed in claim 56, wherein, said derivatives lowers the glycerol (GLY) concentration by about 20 %.

Claim 74. (currently amended): A composition as claimed in claim 73, wherein said derivatives lowers the glycerol concentration by about 14 %.

Claim 75. (original): A composition as claimed in claim 56 wherein said derivatives lower the glucose concentration in about 30 min to 10 hours during post drug administration.

Claim 76. (original): A composition as claimed in claim 75 wherein said derivatives lower the glucose concentration in about 1 hr to 7 hrs during post drug administration.

Claim 77. (currently amended): A method for treatment or prevention of cardiovascular disorders and hyperglycemia (diabetes) by administering a pharmaceutically ~~pharmaceutical~~ effective dosage of ω-naphthyloxy amino alkane derivatives having structural Formula ~~1~~ I,



I

Wherein R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon atoms, ~~such as~~selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, and hexyl; a

branched chain lower alkyl ~~such as~~ selected from the group consisting of isopropyl, isobutyl~~,~~ and t-butyl ~~etc.~~; a cyclic alkane ~~such as~~ selected from the group consisting of cyclopropyl, cyclobutyl, cyclohexyl~~,~~ and cycloheptyl ~~etc.~~; a lower alkoxy in which the alkyl group is as mentioned above, n is 1 to 6; R_3 and R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined above; an aryl residue ~~such as~~ selected from the group consisting of phenyl, substituted phenyl~~,~~ and naphthyl; an arylalkyl residue ~~such as~~ selected from the group consisting of benzyl ~~,~~and substituted benzyl, form a part of a heterocylic ring ~~such as~~ selected from the group consisting of pyrrolidine~~,~~ and piperidine, form ~~a~~ heterocylic ring with additional heteroatoms O,N,S ~~such as~~ selected from the group consisting of piperazine, morpholine, oxazole, oxathinazole and~~,~~ oxathiazine ~~and compounds thereof~~; an alkoxy carbonyl alkane ~~such as~~ represented by the formula R_6COOR_7, wherein R_6 is $(CH_2)n$ (n=1-3) and R_7 is a lower alkyl as defined above, optionally along with acceptable salt/s, carrier/s or dilutent/s~~.~~, wherein the salts/carriers/diluents are selected from the group consisting of lactose, sodium chloride, potassium chloride, magnesium sulphate, magnesium chloride, potassium sulfate, sodium sulfate, lithium sulphate, sodium phosphate, potassium phosphate, magnesium succinate, sodium carbonate, sodium sulfate, potassium acid phosphate and calcium bicarbonate.

Claim 78. (canceled):

Claim 79. (currently amended): A method as claimed in claim 77 wherein said ~~the~~ derivatives ~~include~~ are selected from the group consisting of:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]amine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl] amine-[I: R_1= R_2=H, R_3= propyl R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester- [I: R_1=R_2=H, R_3=CH_2COOEt,R_4=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I:R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)butylamine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=3]

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H,R_4= benzyl, n=4]

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I : R_1 = R_2 = R_3 = H, R_4 = cylohexyl-, n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I : R_1 = R_2 = R_3 =H, R_4 = cylohexyl,n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H, R_4 = cylohexyl,n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]amine [I : R_1 = R_2 = R_3 = H,R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=2-ethyl- n-hexyl, n=3].

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl] amine[I:R_1=R_2=R_3=H ,R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3= H,R_4= n-dodecyl,n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1= R_2 = R_3 = H, R_4=n-dodecyl,n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2= R_3= H,R_4= n-dodecyl,n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2 = R_3 = H,R_4= isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]amine[I:R_1=R_2=R_3=H R_4 = isoamyl, n =3]

(xxviii)N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I : R_1 = R_2 = R_3 = H , R_4 = isoamyl,n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:R_1=R_2= R_3=H , R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1=R_2=R_3= H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=2]

(xxxiii)N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=3]

(xxxiv)N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-butyl, n=4]

(xxxvi)N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl- ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=4]

(xxxix)N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propyl]amine, [I, R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4-Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl] amine. [I, R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl] amine[I,R_1=R_2=H, R_3= n-butyl, R_4=4-Methoxyphenyl, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester[I, R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-Methoxyphenyl, n=3]

(xlviii) 2,7-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

and

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl].

Claim 80. (original): A method as claimed in claim 77, wherein the dosage of the said derivatives is in the range of about 250-350 μmol/Kg.

Claim 81. (currently amended): A method as claimed in claim 80, wherein the dosage of the said derivatives is ~~preferably~~ about 300 μmol/Kg.

Claim 82. (original): A method as claimed in claim 77, wherein the said derivatives may be administered in form of syrup, capsule, tablet, suspension or intravenous.

Claim 83. (currently amended): A method as claimed in claim 77, wherein the method of administration of said derivatives ~~are~~is oral, nasal, or parenteral.

Claim 84. (original): A method as claimed in claim 77, wherein said derivatives lower the concentration percentage of cholesterol by about 30%.

Claim 85. (currently amended): A method as claimed in claim 84, wherein said derivatives lowers the concentration of cholesterol ~~preferably~~ by about 26%.

Claim 86. (original): A method as claimed in claim 77, wherein said derivatives lower the concentration of phospholipid by about 35 %.

Claim 87. (currently amended): A method as claimed in claim 86, wherein said derivatives lower the concentration of phospholipid ~~preferably~~ by about 30%.

Claim 88. (original): A method as claimed in claim 77, wherein said derivatives lower the concentration of triglyceride by about 50 %.

Claim 89. (currently amended): A method as claimed in claim 88, wherein said derivatives lower the concentration of triglyceride ~~preferably~~ by about 48%.

Claim 90. (original): A method as claimed in claim 77, wherein said derivatives enhance the concentration of high-density lipoprotein (HDL) by about 20 %.

Claim 91. (currently amended): A method as claimed in claim 90, wherein said derivatives enhance the concentration of high-density lipoprotein ~~preferably~~ by about 15%.

Claim 92. (original): A method as claimed in claim 77, wherein said derivatives lower the glucose (GLU) concentration by about 40 %.

Claim 93. (currently amended): A method as claimed in claim 92, wherein said derivatives lower the glucose (GLU) concentration ~~preferably~~ by about 30 %.

Claim 94. (original): A method as claimed in claim 77 wherein said derivatives lower the glycerol (GLY) concentration by about 20 %.

Claim 95. (original): A method as claimed in claim 94 wherein said derivatives lower the glycerol concentration by about 14 %.

Claim 96. (original): A method as claimed in claim 77, wherein said derivatives lower the glucose concentration in about 30 min to 10 hours during post drug administration.

Claim 97. (original): A method as claimed in claim 96, wherein said derivatives lower the glucose concentration in about 1 hr to 7 hrs during post drug administration.